PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Genedata

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Genedata Collaboration Yields New Hit to Lead Solution - Genedata announces the release of a new analysis module for identifying lead compounds. The module was developed alongside experts at Altana Pharma and enables visualization, annotation and compound filtering on biological and chemical parameters
Genedata Collaboration Yields New Hit to Lead Solution

 

NewswireToday - /newswire/ - Basel, Switzerland, 2006/09/12 - Genedata announces the release of a new analysis module for identifying lead compounds. The module was developed alongside experts at Altana Pharma and enables visualization, annotation and compound filtering on biological and chemical parameters.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Enterprise screening analysis provider Genedata announces the release of a powerful new analysis module for identifying lead compounds from high throughput screening results. The module was developed alongside screening experts at international pharmaceutical company Altana Pharma and enables visualization, annotation and detailed compound filtering on biological and chemical parameters.

New release Hit Profiler exploits semantic integration technologies to display screening results and a diverse range of compound information in a compound-centric, interactive table environment. Semantic integration ensures that multiple concentration data is displayed as dose response curves, that SMILES information is rendered as chemical structures, and so on.

Dr. Werner Stuermer, Head of HTS, Altana Pharma, worked closely with Genedata’s Screener team during development of the module. Altana sought to filter lists of active and selective hits on the basis of biological and chemical considerations, including ADME/Tox information corresponding to chemical classes. According to Dr. Stuermer, “lead selection has moved beyond simple activity and selectivity considerations and has become a truly multidimensional exercise”.

A brief look at this year’s Society for Biomolecular Sciences conference program confirms the widened scope and sheer number of parameters used in lead selection. Hit Profiler adheres to industry standards and can thus capture all kinds of discovery-relevant information. Stuermer added, “Bringing together all that information is a significant bioinformatics challenge”.

“We developed Hit Profiler to satisfy a need for concise hit and lead assessment”, explained Dr. Stephan Heyse, Head of Genedata Screener. Genedata has a successful and long-standing collaboration with Dr. Stuermer’s team at Altana Pharma. Dr. Heyse added, “The collaboration reflects Altana’s strong commitment to innovation-driven drug discovery”.

Announcement: Genedata’s Dr. Stephan Heyse will present at next week’s Society for Biomolecular Sciences 12th annual meeting in Seattle, Washington, USA.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Genedata

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Genedata Collaboration Yields New Hit to Lead Solution

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Dr. Tobe Freeman - Genedata.com 
+41 61 697 8510 tobe.freeman[.]genedata.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Genedata securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Genedata / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  S&A Capital Partner Ltd

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)